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Endometriosis is a common inflammatory estrogen-dependent gynecological disorder, associated 
with pelvic pain and reduced fertility in women. Several aspects of this disorder and its cellular and 
molecular etiology remain unresolved. We have analyzed the global gene expression patterns in 
the endometrium, peritoneum and in endometriosis lesions of endometriosis patients and in the 
endometrium and peritoneum of healthy women. In this report, we present the EndometDB, an 
interactive web-based user interface for browsing the gene expression database of collected samples 
without the need for computational skills. The EndometDB incorporates the expression data from 115 
patients and 53 controls, with over 24000 genes and clinical features, such as their age, disease stages, 
hormonal medication, menstrual cycle phase, and the different endometriosis lesion types. Using the 
web-tool, the end-user can easily generate various plot outputs and projections, including boxplots, 
and heatmaps and the generated outputs can be downloaded in pdf-format.
Availability and implementation: The web-based user interface is implemented using HTML5, JavaScript, 
CSS, Plotly and R. It is freely available from https://endometdb.utu.fi/.
Background & Summary
Endometriosis is a common, chronic, and benign estrogen-dependent gynecological disorder associated with 
inflammation, pelvic pain, and reduced fertility in affected women. The prevalence of endometriosis in reproduc-
tive aged women varies between 5–10%, while the frequency in women with pelvic pain with or without infertility 
is between 50–60%1–3. Endometriosis is characterized by the presence of endometrium-like tissue growing in 
ectopic locations outside the uterine cavity. The ectopic lesions respond to ovarian derived steroid hormones, with 
a tendency for recurrence after surgical treatment1. The etiology and pathogenesis of endometriosis is multifac-
torial and still poorly understood, and the current treatment strategies, including pharmacological therapies, are 
not curative and often do not alleviate the pain symptoms4,5.
In classifying endometriosis, the proposed disease classification by the American Society of Reproductive 
Medicine (ASRM) is the most widely used. It provides a standard form for reporting pathological findings, 
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together with a numeric value for the disease status6. The ASRM classification assigns points based on the spread 
of the endometriosis tissue, its infiltration depth in ectopic sites, and the areas of the body affected.
In this report, we present the EndometDB, an interactive web-based user interface easily applicable for brows-
ing the gene expression database of collected samples without the need for computational skills. The patient fea-
tures associated with the lesions within the EndometDB can be used as stratifying factors when investigating the 
gene expression patterns. Endometriosis type can be defined also by its clinical appearance and by which area of 
the pelvis or abdomen the lesions affect: Ovarian endometrioma, peritoneal endometriosis lesion, and deep infil-
trating lesion, and all these features are available to be linked to the mRNA expression data in the EndometDB. 
Similar to the eutopic endometrium, endometriosis progression is highly dependent on sex steroid action, and 
the lesion growth is highly dependent on estrogen stimulus7. Due to the strong sex steroid dependency, hormonal 
treatments, e.g. with oral contraceptives, that suppress ovarian steroid hormone action are used to reduce the 
lesion growth and manage the pain symptoms. In the EndometDB, the gene expression can be associated with the 
menstrual cycle, hormonal medication status of the affected women and the ASRM disease classification.
Comparing the gene expression profiles of disease tissue to that of a normal healthy tissue is a powerful 
approach to understand the underlying cellular events in the etiology of any disease8. Accordingly, gene expres-
sion changes associated with endometriosis have also been analyzed in previous studies using various microarray 
platforms by comparing the endometriosis lesions with eutopic endometrial tissues9–13, or by comparing the 
endometrium of the patients to that of healthy controls14–16. All these studies have offered some essential under-
standing into the transcriptional differences related to endometriosis, however, only a limited number of samples 
were included due to various constraints, with samples size ranging from between 6 and 25. To address this lim-
itation, the Endomet database includes the most extensive collection of lesions so far analyzed for genome-wide 
mRNA expression. Furthermore, several studies have analyzed only the ovarian lesions10,17, largely due to the 
ample availability of such samples.
Overall, the field of endometriosis study is primed to further characterize and describe specific pathways 
involved in the disease and there is still a need for more systematic and comprehensive analysis of the gene 
expression patterns across different types of endometrial lesions as the different forms of endometriosis may 
express different markers/genes differently18. Analyzing different lesion types could aid in the identification of 
the potential diversity in the etiology of the different lesion types. As an example, using the data included in 
the EndometDB we identified Secreted frizzled-related protein 2 (SFRP2) to be a gene with high expression in 
endometriosis compared to the endometrium. The protein was shown to be a novel lesion border marker in histo-
logical sections, and as a secretory protein it has a potential to serve also as a serum biomarker19. The current ver-
sion of the EndometDB consists of structured mRNA expression information from 115 patients and 53 controls 
(Table 1), with the data available from 190 lesions of different types. The EndometDB can be explored through 
several patient factors, such as age, cycle phase, disease stage and hormonal medication status. The tissues are 
histologically confirmed, and the mRNA expression on patient and healthy endometrium and peritoneum can 
also be analyzed. The database integrates clinical data (Fig. 1a) and tissue types (endometrium, peritoneum and 
the different endometriosis lesion types) with the transcriptomic data (>48000 measured), and the graphical user 
interface (GUI) allows easy access to the curated data. The entire transcriptomic data in the EndometDB can be 
Parameter Patient group (n = 115) Control group (n = 53)
Mean age (SD, range) 32 (6.8, 20–48) 39 (4.7, 24–48) *** a
Median BMIb (range) 23 (17.3–40.6) 24 (18.9–41.2)
rAFS stage
  I 15 (8.9%) NA
  II 15 (8.9%) NA
  III 26 (15.5%) NA
  IV 56 (32.2%) NA
  Missing Data 3 (1.8%) NA
Indication for surgery
  Pain 71 (42.3%) NA
  Infertility 6 (3.6%) NA
  Both pain and infertility 22 (13.1%) NA
  Clinical finding in gynecological examination 15 (8.93%) NA
  Not recorded 1 (0.6%) NA
Menstrual cycle phase
  Proliferative 19 (11.3%) 14 (8.3%)
  Secretory 26 (15.5%) 12 (7.1%)
  Menstrual 6 (3.6%) 1 (0.6%)
  Inactive, atrophic or insufficient 51 (30.4%) 18 (10.7%)
  Missing Data 13 (7.7%) 8 (4.8%)
Table 1. Clincal characteristics of patients with endometriosis and healthy controls used in the present study. 
Note: BMI = Body mass index; NA = not applicable; NS = not significant, a*** < 0.0001, Two-sample t-test, 
bBMI missing 2 (2%) in the patient group and 2 (4%) in the control group.
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explored all at once or in subsets. The users can choose whether they perform the expression analysis based on 
all expression data of over 24000 genes or on only the genes of interests (Fig. 1b). The EndometDB with detailed 
transcription profiles of eutopic and ectopic endometrium is a valuable tool for identifying potential biomarkers 
and treatment targets, and to gain novel information on the gene expression networks associated with the lesion 
growth. This in turn could aid the development of novel diagnostic and prognostic markers predictive of endo-
metriosis and to understand the pathogenesis of endometriosis better.
Methods
Ethics approval and informed consent. The study protocol was approved by the Joint Ethics Committee 
of Turku University and Turku University Central Hospital in Finland and registered in Clinical Trials.gov as trial 
number NCT01301885. Prior to surgery a written informed consent for participation in the study was required 
from all the study subjects. All specimen collected are part of the Auria biobank sample collection (https://www.
auria.fi/biopankki/en/index.php?lang = en). The sample collection protocol closely resembles those recom-
mended by World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization 
Fig. 1 (a) Schematic overview of the EndometDB used for transcriptomic analysis. The questionnaire data is 
collected through the Webropol survey system and imported into EndometDB via an automated service layer API. 
The numerical results of the biomedical samples analyzed are uploaded into the system together with the sample 
information. The uploading is done through the web user interface. Analytical functions are available through 
the analysis engine and can be used to query the whole data set. (b) EndometDB web graphical user interface 
(GUI) analysis process. The GUI, through a client, communicates with the analysis engine through an API layer 
implemented with PHP. The analysis engine analyzes the data using the R programming language and Plotly 
graphing library with the ggplot2 R package is used to generate the plots that are transferred back to the GUI.
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Project and the Endometriosis Phenome and Biobanking Harmonization Project WERF/EpHECT20–24, despite 
carrying out the collection before those recommendations were published.
Study design. This study was conducted at the Department of Obstetrics and Gynecology Turku University 
Hospital, University of Turku, Finland, and the Institute of Biomedicine, Research Centre for Integrative 
Physiology and Pharmacology, University of Turku, Finland. Samples of endometriosis, eutopic endometrium 
and peritoneum were collected from endometriosis patients, at 4 different hospitals in Finland and healthy tissues 
from the endometrium and peritoneum were obtained from women undergoing laparoscopic tubal ligation at the 
Turku University Hospital, University of Turku, Finland. A definitive diagnosis was reached through laparoscopy 
or laparotomy, and endometriosis was further confirmed by histopathological evaluation of obtained biopsies. 
Endometriosis was excluded by laparoscopy during tubal sterilization in healthy women. The menstrual cycle 
stage was determined at the day of sampling using a questionnaire, endometrial histology, and serum progester-
one concentration. Three different endometriosis sample subtypes were collected for transcriptional analysis: 1) 
deep infiltrating endometriosis lesions (DiE), including deep rectovaginal (REV), sacrouterine ligament lesion 
(SuL), intestinal endometriotic lesions (DiEIn) and deep endometriotic lesions in the bladder (DiEB); 2) perito-
neal endometriosis lesions, including red peritoneal endometriotic lesion (PeLR), black peritoneal endometriotic 
lesion (PeLB) and white peritoneal endometriotic lesion (PeLW); and 3) ovarian endometrioma samples (OMA). 
Endometrium samples from both patients (PE) and healthy controls (CE) were collected, as well as peritoneum 
samples from both healthy controls (CP) and patients (PP). Patient characteristics are presented in Table 1, and 
the samples used in the transcriptomic analysis are described in Table 2. All tissues used for mRNA analyses were 
snap-frozen and stored in liquid nitrogen within 10 min, until used.
PostgreSQL relational database. To implement the EndometDB, we used PostgreSQL (https://www.
postgresql.org/), an open-source object-relational database management system (ORDBMS) that allows for the 
handling of workloads ranging from small-machine application to large internet scale applications with many 
concurrent users. The PostgreSQL database stores information and metadata on a Linux server that efficiently and 









Control endometrium 43 14 12 10 7
Patient endometrium 101 16 28 43 14
Ovarian endometriosis 28 7 9 7 5
Peritoneal endometriosis 76 13 15 37 11
Deep endometriosis 86 9 16 48 13
Control peritoneum 24 3 6 12 3
Patient peritoneum 38 4 9 15 10
rAFS stage
  I–II 30 3 8 14 5
  III 26 7 5 10 4
  IV 56 9 12 26 9
  Missing 3 1 1 1

















Plotly graphing library https://plot.ly/r/
ggplot2 R package https://www.rdocumentation.org/packages/ggplot2/versions/3.1.1
ORCA https://www.rdocumentation.org/packages/plotly/versions/4.9.0/topics/orca
Table 3. List of programming languages.
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the EndometDB to allow for smooth communication between server and clients (web browser on computers, 
tablets, etc.) which is specifically adapted for sending SQL queries to the database and serving the results in stand-
ardized format to the client. In addition, it interfaces with the analysis engine which itself sends custom queries to 
the database to retrieve measurement data for statistical analysis and visualization. This stable architecture can be 
also extended to future needs arising from new functionalities developed on different platforms.
Web-based graphical user interface. The EndometDB is implemented on an Ubuntu Linux system and 
incorporates a GUI that utilizes HTML5, JavaScript, PHP, and R as the main programming languages. The GUI 
also uses jQuery, Plotly.js, and CSS for the frontend styling, and the graph visualizations are generated with the 
Plotly R open source graphing library. The GUI was developed to accommodate both physicians and researchers 
with the two modes separated by user-based authentication. The publicly available part features an informational 
Fig. 2 EndometDB GUI. Screenshot of the EndometDB user interface showing tabbed browsing functions (on 
the left) and an example boxplot (HSD17B2) as an output of a gene analyzed (on right). The browsing functions 
include controls for interacting with the filters such as the clinical data (age, menstrual cycle phase, hormonal 
medication, disease stage), sample data (tissue type; endometrium, peritoneum, endometriosis lesions) and 
plots and projections. The different color boxplot represents the different tissues and lesions for both the healthy 
women and patients. The colors make it easier to distinguish between the different tissues and lesions as well as 
between healthy controls and patients.
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site with pages for research overview, team members, collaborating partners and contact details, as well as a 
comprehensive set of analytical tools for data visualization and basic statistical assessment of transcriptomic data. 
The GUI allows users, through a client, to send requests to the analysis and visualization engine via an API layer 
implemented with PHP. The analysis engine is implemented as a S3 R package and utilizes several R packages for 
statistics and graphical output, in particular ggplot225, Plotly and HTML widgets, to generate a JSON representa-
tion of the plots which is then transferred via the Plotly JavaScript Open Source Graphing Library back to the GUI 
where it is displayed in the user’s browser. We also used the Open source Report Creator App R Package (ORCA) 
on the backend to allow the user to render the generated plot to PDF (Fig. 1b). List of programming language and 
URL in Table 3. The design of the EndometDB web graphical user interface enables users to search and analyze 
the data in the database without the need for computational skills, and can search data related to a gene(s) of 
interest by typing or copy pasting the gene symbol(s) into the designated area (Fig. 2).
The GUI incorporates different techniques and analytical methods to analyze transcriptomic data. The 
EndometDB GUI allows users to browse and view data in tabbed sections, rather than having to open multiple 
pages that take up computing resources (Fig. 2). One of the many techniques and analysis methods the EndometDB 
GUI provides, relies on filter-based data mining which allows mRNA expression of genes of interest in various 
endometriosis lesion types, and in the endometrium and peritoneum from both controls and patients, and clinical 
features such as age, menstrual cycle phase, hormonal medication, and disease stage which can be used for strati-
fication, be displayed for instance, with boxplots (Fig. 2) which shows the range of the data distribution. Users can 
also choose to simultaneously compare expression patterns between different genes of interests or pathway genes. 
These comparisons can then be displayed e.g. with a heatmap (Fig. 3) and be summarized by either the median or 
mean, and the user may further center the data using the gene or lesion. Users can display the heatmaps using differ-
ent unsupervised hierarchical clustering algorithms (Complete linkage, Single linkage, Average linkage, or Ward’s 
method), and with predefined distance methods (Euclidean, Canberra, Manhattan, Maximum, or Minkowski).
Clinical features such as age, menstrual cycle phase, hormonal medication, and disease stage can also be used 
as contrast in the hierarchical clustering to show how groups of genes relate to these clinical features. Users can 
also use the correlation heatmap feature (Fig. 4) with the most used correlation methods (Pearson, Spearman, and 
Kendall), to show the correlation matrix between two discrete dimensions. The correlation heatmap can also be 
Fig. 3 Example output of unsupervised hierarchical clustering analysis generated via the EndometDB GUI. 
Example of unsupervised hierarchical clustering analysis of mRNA expression of the differentially expressed 
WNT pathway genes (Online-only Table 1) in all the sample groups. The different clinical features of the 
samples (lesion/tissue type, age of the patients with pre-selected grouping, hormonal stage, and disease stage) 
are attached to the heatmap. Canberra distance metric with Ward’s clustering method was applied showing 
clusters corresponding to lesions and tissue types. The dendrogram on the x-axis shows the hierarchical 
relationship between the tissues and lesion as well as the cycle phase and disease stage. While the dendrogram 
on the y-axis shows the measure of similarities in the activation levels of the WNT signaling pathway genes. The 
colors represent different tissues and lesions from both healthy controls and patients.
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clustered using the most used hierarchical clustering methods to analyze how genes of interest correlate with each 
other in the different lesions or tissues. These methods provide information about the involvement of analyzed 
genes in the connected biological processes.
To further investigate similarities in the gene expression, e.g., between the various sample types or to identify 
gene clusters to generate further hypotheses, the EndometDB web GUI tool includes three dimensionality reduc-
tion methods: Principal Component Analysis (PCA, Fig. 5a), Local Fisher Discriminant Analysis (LFDA, Fig. 5b) 
and Multidimensional scaling26. Users can also choose to display the scree plot that shows how much each of the 
PCA components accounts for the total variance in the gene expression data26. The principal components in the 
scree plot are listed by decreasing order of contribution to the total variance and the bars in the output show the 
proportion of variance represented by each component. Users are can also choose to color the PCA using pre-
defined groups such as tissues, subject class, disease stage, menstrual cycle phase, and age as well as display the 
confidence ellipses that shows the variability in the data (Fig. 5a). The confidence ellipse label can be viewed when 
users mouse-over the generated plot or by selecting the label ellipses checkbox.
In the EndometDB the LFDA may be used to find a linear combination of genes that characterize or sep-
arate two or more sample classes, and simultaneously maintain the local structure of the expression data. 
Three metric types can be used in the EndometDB with LFDA (Raw eigenvectors, Weighted eigenvectors, and 
Orthonormalized), and colored by predefined groups (Fig. 5b). MDS is a technique used in detecting and visu-
alizing meaningful underlying dimensions that allows for researchers to explain observed similarities or dissim-
ilarities (distances) between the investigated samples26. Defined distance methods such as Euclidean, Canberra, 
Manhattan, Maximum, and Minkowski can be used with MDS for visualization of the similarities or dissimilari-
ties and colored by these predefined groups (tissues, subject class, disease stage, menstrual cycle phase, and age).
Interactive visualization. The interactive visualization is implemented using the Plotly open source 
JavaScript graphing library (https://plot.ly/javascript/). This provides the EndometDB GUI users with interac-
tive features (Fig. 2). The interactive visualization has four components: 1) Hover data, which allows users by 
mouse-over to view values within the graph; 2) Click data, which allows users to click on points in the graph; 3) 
Selection data, which allows users to choose the lasso or rectangle tool in the graph menu bar, and then select 
points of interest in the graph and 4) Zoom and relay out data, which allows the users to click and drag the graph 
to zoom or click the zoom buttons in the graph’s menu bar. These components enable the user, by moving the 
mouse pointer over tiles of the heatmap, or over row/column labels, or the box plot, to display additional infor-
mation. The EndometDB GUI sidebar (Fig. 2) contains controls for interacting with the visualization that allow 
users to select filters such as the clinical data (age, cycle phase, hormonal medication, disease stage), sample data 
(tissue type; endometrium, peritoneum, endometriosis lesions) and various types of plot outputs and statistics. 
Fig. 4 Example of correlation heatmap from the EndometDB generated via the GUI. Correlation heatmap after 
hierarchical clustering of WNT pathway genes (Online-only Table 1) with Pearson correlation method and Ward’s 
clustering method. Clustering dendrogram on both axes show the measure of the relationship between the genes.
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The user can further interact with the generated outputs by clicking on the legend (on the right side of the figure) 
to relay out the data within the plotted graph.
Generating the transcriptomics data by microarrays. The global transcriptomics data of all the tissue 
specimens presented in the EndometDB were generated on the Sentrix® Illumina HumanWG-6 v2 Expression 
BeadChips (Illumina, USA) and Illumina HumanHT-12 v4.0 Expression BeadChips (Illumina, USA) microarray 
platforms. For this, total RNA from snap frozen tissues was isolated using Trizol reagent (Thermo Fisher Scientific, 
USA), and further purified with RNeasy columns (Qiagen, Netherlands), and treated with DNase (RNase-free 
DNase Set, Qiagen, Netherlands; or DNase I, Invitrogen, Thermo Fisher Scientific, USA) to remove genomic 
DNA. The RNA concentrations were determined using Nanodrop ND-1000 spectrophotometer (Thermo Fisher 
Scientific, USA), and the quality of the RNA used was controlled using ExperionTM Automated Electrophoresis 
system (Bio-Rad Laboratories, USA), and the mean RQI value of all the samples were 7.5.
Fig. 5 Example of projection outputs from the EndometDB generated via the GUI. (a) PCA analysis of mRNA 
expression of the differentially expressed WNT pathway genes in all the sample groups. Samples are colored 
by tissue types, and the confidence ellipses with 95% confidence level for the expression in various tissue types 
are generated using the EndometDB GUI. The PCA separates control and patient endometrium from the three 
subtypes of endometriosis lesions. (b) LFDA analysis of WNT pathway genes with raw eigenvectors metric 
colored by tissues. In addition to separating endometriosis lesions from endometrium, LFDA separates ovarian 
endometriosis from peritoneal and deep endometriosis. The list of WNT pathway genes used in these analyses 
are listed in Online-only Table 1.
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Microarray analysis was performed on samples obtained from 190 endometriotic lesions26 (76 peritoneal, 86 
deep and 28 ovarian endometriosis) and from 101 endometrium biopsies of endometriosis patients and 43 endo-
metrium biopsies of control women (Table 2). The hybridized images were scanned using Agilent’s microarray scan-
ner and quantified with Feature Extraction Software (Agilent Technology, CA, USA). Raw intensity data was then 
globally normalized according to manufacturer’s instructions. Data from the Sentrix® Illumina HumanWG-6 v2 
and Illumina HumanHT-12 v4.0 Expression BeadChips were loaded using beadarray R package27. For global cor-
rection, each chip generation was treated as a separate batch. Log transformation and quantile normalization was 
Fig. 6 Validation of microarray result with qRT-PCR. Examples of the mRNA expression for steroid receptors 
(ESR1, PGR), steroid metabolizing enzymes (HSD17B2, HSD17B6), and WNT- pathway genes (SFRP2, and 
MPZL2) analyzed by RT-qPCR (a1, b1, c1, d1, e1, f1) and with the EndometDB (a2, b2, c2, d2, e2, f2).
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performed batch-wise using standard R Bioconductor methods28–30. We used the BLAST Method to map probes to 
their corresponding genes using up-to-date gene-to-probe associations all probe sequences were aligned to NCBI’s 
Nucleotide Sequence (nt) database31 adopting a procedure published in a previous study32. Since aligning to the nt 
database resulted in multiple hits across multiple species data was cleaned and filtered before being used to join the 
different array generations. To extract relevant features from the BLAST results data is annotated with up-to-date 
gene symbols and Entrez IDs. To achieve a more reliable annotation three different sources are used, dbOrg (https://
biodbnet-abcc.ncifcrf.gov/db/dbOrg.php), HGNC (ftp://ftp.ebi.ac.uk/pub/databases/genenames/new/tsv/) and 
BioMart33,34. During the joining process, the symbol found in most of the annotation sources is used.
Combining the microarray data from the two Expression BeadChips data frames obtained from the BLAST 
approach are joined on the Entrez Gene ID and the RefSeq mRNA Accession ID, resulting in 27541 common 
probes corresponding to 24423 genes. To correct the variation originating in the different Expression BeadChips 
array versions the ComBat batch adjustment algorithm35 within the SVA R-Package36 was used. The quality of the 
merged data was then assessed by PCA and global correlation analysis.
Data Records
The EndometDB is freely accessible at https://endometdb.utu.fi/. A copy of EndometDB is also made publicly avail-
able on figshare as a zip file containing a SQL dump of the database26 along with additional supplements data. All 
the raw data for the global transcriptomic data, generated by the Sentrix® Illumina HumanWG-6 v2 Expression 
BeadChips (Illumina, USA)37 and Illumina HumanHT-12 v4.0 Expression BeadChips (Illumina, USA)38 microarray 
platforms used in this study have been uploaded to the National Center for Biotechnology Information (NCBI) Gene 
Expression Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/geo/). The normalized data from both the Sentrix® 
Illumina HumanWG-6 v2 Expression BeadChips (Illumina, USA) and the Illumina HumanHT-12 v4.0 Expression 
BeadChips (Illumina, USA) as well as the combined normalized data from both microarray platforms in the 
EndometDB have also been uploaded to GEO with the series accession number GSE14154939. The deposited data 
contains non normalized data matrix from both platforms as well as processed transcriptomic data files, together 
with the clinical features described in this report. This manuscript describes the samples, data collection, processing 
steps, and the EndometDB with freely available GUI for data analysis and interactive visualization.
Technical Validation
Quality control of RNA integrity. To determine RNA quality, ExperionTM Automated Electrophoresis 
system (Bio-Rad Laboratories, USA) was used. The integrity of RNA was calculated using RQI (RNA quality 
indicator) algorithm, where a high number indicates higher quality, with the maximum value being 10. The mean 
RQI value of all samples was 7.5 and the lowest acceptable RQI was > 6.
Primer 
name Accession No. Sense Primer (5′ → 3′) Antisense Primer (5′ → 3′)
Target 
length
RPL19 NM_000981.4 AGGCACATGGGCATAGGTAA CCATGAGAATCCGCTTGTTT 199
CYP19A1 NM_001347248.1 AGTGCATCGGTATGCATGAG AGAAGGGTCAACACGTCCAC 205
HSD17B2 NM_002153.3 AACTGATGGGGAGCTTCTTCTTAT CCTCCTCCCATGCTGCTGACA 147
HSD17B6 NM_003725.4 CTCCAGCATTCTGGGAAGAG AATATGCTTGGGGGCTTCTT 217
ESR1 NM_000125.3 TGGATTTGACCCTCCATGAT GATCTCCACCATGCCCTCTA 170
ESR2 NM_001437.2 TATCACATCTGTATGCGGAACC TACATCCTTCACACGACCAGAC 225
AR NM_000044.4 TGGCGGGCCAGGAAAGCGAC GGGCAAAACATGGTCCCTGGCA 179
HGD NM_000187.4 CTCTCAGGATCGGCTTTCAC TGTCTCCAGCTCCACACAAG 244
MPZL2 NM_005797.4 GGGACAGATGCTCGGTTAAA CAAGACACCCGGTCCTTAAA 173
PDGFRL NM_006207.2 AAAAGTGGGGACGACATCAG GGGAGATTCTCGTGGTGTGT 166
SMTN NM_134270.2 GAGTCTGCCCAAGACCTCAG AGTCTTGGCTCGACACCAGT 181
SRD5A3 NM_024592.5 TCCTTCTTTGCCCAAACATC CTGATGCTCTCCCTTTACGC 211
TRH NM_007117.5 CTGAAGCGTTGTGTGCAAAT AGCCAGACACAGCACAACAC 204
STS NM_000351.5 CATGGACATATTTCCTACAGTAGCC GATCACGTCCATCAATGATCC 77
PRUNE2 NM_015225.3 CAGAAAACATGGAGCTGTGC AAAGGGCTCCAGTTCTAGGC 80
DKK1 NM_012242.4 TCCGAGGAGAAATTGAGGAA CCTGAGGCACAGTCTGATGA 157
DKK3 NM_015881.5 ACAGCCACAGCCTGGTGTA CCTCCATGAAGCTGCCAAC 120
FZD7 NM_003507.1 GGCTGCGCTGCGAGAACTTC CAGCGCGGTGAAGGGCAGGTC 146
FZD10 NM_007197.3 CCTCCAAGACTCTGCAGTCC GACTGGGCAGGGATCTCATA 160
FRZB NM_001463.4 GCAAGCAGTGAACGCTGTAA GGCAGCCAGAGCTGGTATAG 214
HPRT1 NM_000194.3 TGCTCGAGATGTGATGAAGG TCCCCTGTTGACTGGTCATT 192
SFRP1 NM_003012.5 CGAGTTTGCACTGAGGATGA CAGCACAAGCTTCTTCAGGTC 130
SFRP2 NM_003013.3 CGAGGAAGCTCCAAAGGTAT CTCCTTCACTTTTATTTTCAGTGCAA 112
WNT5A NM_003392.4 TGGCTTTGGCCATATTTTTC CCGATGTACTGCATGTGGTC 199
WISP2 NM_001323370.1 CTGTATCGGGAAGGGGAGAC GGAAGAGACAAGGCCAGAAA 246
Table 4. List of primers used for quantitative real-time PCR.
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Quality control of microarray profiling. The normalized RNA data was quality controlled using the 
ArrayQualityMetrics R package40.
Validation of the microarray data using quantitative reverse transcription PCR (RT-qPCR). To 
validate the transcriptomic data provided in the EndometDB by an independent method, we performed RT-qPCR 
analyses for various transcripts of selected enzymes involved in steroid synthesis, of certain androgen regulated 
genes and certain WNT signaling pathway genes41–43 (Online-only Table 1) in the ovarian, deep, peritoneal 
lesions and endometrium (Fig. 6). For those analyses we used 0,5 μg. of total RNA that was converted to cDNA 
using the DyNAmo HS SYBR Green 2-Step RT-qPCR kit (Finnzymes, Thermo Fisher Scientific, USA), followed 
by the qPCR reactions for 40 cycles with the primers presented in Table 4. Ribosomal protein L19 (RPL19) was 
used as reference gene for the data normalization. The RT-qPCR analyses were carried out in samples26 obtained 
from the proliferative and secretory phase samples of OMA (n = 10–18), DiE (n = 10–16), PeL (n = 10–19), 
and PE (n = 6–20). Endometrium and peritoneum of healthy women (CE, CP) and patients (PE, PP) were also 
included (n = 8–21). The expression ratio was calculated using the mathematical model for relative quantification 
in real-time PCR44. The ratio represents the factor by which the target gene of interest is expressed in endometri-
osis relative to patient eutopic endometrium after normalization to the reference gene.
Usage Notes
The EndometDB in its current form does not allow for others to add curated data of their own. However, we are 
open to adding data also from other groups in the field. To ensure that all investigators have an easy access to the 
data in our EndometDB, we developed a web application using HTML5, JavaScript, CSS, JS-libraries: jQuery, 
Plotly.js and R. Any internet enabled device using a modern browser can access the EndometDB (https://endo-
metdb.utu.fi/). No user account needs to be created to access or use the features incorporated for exploration of 
the genes in the GUI. In exploring the EndometDB, users can:
 1. View summary characteristics of the EndometDB.
 2. Explore differentially expressed genes in endometrium, peritoneum, and endometriosis lesion.
 3. Cluster genes across the above-mentioned tissues and lesions.
 4. Explore how genes correlate with each other in the above-mentioned tissues and lesions.
 5. Performing projections of data with PCA, MDS and LFDA.
Code availability
EndometDB uses open source components listed in the Table 3. Code for pre-processing of the data is available 
upon request. The Expression BeadChips were loaded using R function calls in the publicly available beadarray 
R package27. Log transformation and quantile normalization was performed using standard Bioconductor R 
packages28–30. The ComBat batch adjustment algorithm35 within the SVA R-Package36 was used to correct the 
variation in the different Expression BeadChips arrays. The EndometDB source code is available at our GitHub 
repository https://github.com/micawo/EndometDB.
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